Abstract:Tumor evolution is associated with drug resistance. Leptomeningeal metastasis (LM) is a fatal complication in patients with NSCLC. The blood-brain barrier protects the central nervous system from toxicity, but also prevents most therapeutic agents from accessing the brain parenchyma and leptomeningeal space.1Cheng H. Perez-Soler R. Leptomeningeal metastases in non–small-cell lung cancer.Lancet Oncol. 2018; 19: e43-e55Abstract Full Text Full Text PDF PubMed Scopus (147) Google Scholar Because of lower selection pressure, LM may evolve more slowly than extracranial lesions. A 58-year-old male patient with a 25-pack/year smoking history presented with cough in November 2016. The flow chart of diagnosis and treatment is shown in Figure 1. No abnormalities were found in brain enhanced magnetic resonance imaging. The patient was diagnosed with lung adenocarcinoma with pleura and right ilium metastases, cT2N2M1 (stage IV, EGFR exon 19 deletion). He developed primary pulmonary lesion transforming into squamous cell carcinoma and LM after drug resistance to afatinib. Plasma and cerebrospinal fluid (CSF) samples were collected for cell-free DNA extraction and subsequently examined by targeted next-generation sequencing (NGS) for 139 lung cancer–related genes (Supplemental Table 1) to a mean coverage depth of above 4500× (Illumina Hiseq, Illumina, San Diego, California). Tumor tissue was also tested by targeted NGS (Table1). The NGS results showed that EGFR mutation disappeared in peripheral blood and lung lesions, whereas EGFR exon 19 deletion mutation persisted in CSF (Figs. 2B–D). The addition of osimertinib on the basis of chemotherapy and bevacizumab resulted in rapid and long-term improvement in the symptoms of LM. The patient subsequently developed liver metastasis, which was confirmed by biopsy as squamous cell carcinoma. Interestingly, another EGFR mutation was found in the liver metastasis: EGFR exon 20 insertion(EGFR p. P772 delinsPHA) rather than the original exon 19 deletion (Figs. 2E and F).The level of serum squamous cell carcinoma antigen was gradually elevated during the course of the disease, whereas the level of serum carcinoembryonic antigen remained close to normal (Fig. 3).Table 1NGS Results of Different Times and Locations During the Disease Course of the PatientBefore TreatmentAfter Afatinib TreatmentAfter Liver MetastasisLungSerumLungCSFSerumLiverVariationVAFVariationVAFVariationVAFVariationVAFVariationVAFVariationVAFEGFRp.745_750del (c.2235_2249delGGAATTA AGAGAAGC)26.6%---p.745_750del (c.2235_2249delGGAATTA AGAGAAGC)53.4%p.P772delinsPHA (c.2314_2315 insCCCACG)1.1%p.P772delinsPHA (c.2314_2315 insCCCACG)1.5%EGFR--------Amplification3.9 timesAmplification10.7 timesPIK3CAp.H1047R34.8%--Amplification2.7 timesp.H1047R48.7%----RB1----Single copy loss-----TP53----p.S127Y87.7%Single copy loss-p.S127Y11.3%p.S127Y70.0%TP53--------Single copy lossKDR----p.D120G24.3%--p.D120G12.3%p.D120G21.5%KIT----Amplification10 times--Amplification2.2 timesAmplification3.4 timesLRP1B----p.D4156Y55%--p.D4156Y11.2%p.D4156Y50.5%SOX2----Amplification3.7 times----Amplification2.0 timesTET2----p.Q734X90.3%--p.Q734X26.7%p.Q734X82.3%CSF, cerebrospinal fluid; VAF, variant allele frequency; NGS, next-generation sequencing. Open table in a new tab Figure 2Visualization of EGFR mutations in the case using the Integrative Genomics Viewer (IGV). IGV display of (A) EGFR 19Del in a primary lung biopsy specimen, and of EGFR 19Del after progression of afatinib treatment in (B) plasma, (C) lung biopsy, (D) cerebrospinal fluid specimens, and of EGFR 20 Ins after liver progression in (E) plasma and (F) liver biopsy specimens.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3The variation curves of carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCCA).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3The variation curves of carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCCA).View Large Image Figure ViewerDownload Hi-res image Download (PPT) CSF, cerebrospinal fluid; VAF, variant allele frequency; NGS, next-generation sequencing. In this case, the transformation of adenocarcinoma to squamous cell carcinoma in primary pulmonary lesion was accompanied by the loss of EGFR mutation. Nevertheless, EGFR 19Del mutation persisted in CSF. Thus, the LM symptoms were quickly alleviated by osimertinib, which has remarkable efficacy in EGFR-mutated NSCLC patients with LM.2Tan C.S. Cho B.C. Soo R.A. Treatment options for EGFR mutant NSCLC with CNS involvement — can patients BLOOM with the use of next generation EGFR TKIs?.Lung Cancer. 2017; 108: 29-37Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar More interestingly, after subsequent treatment, the patient developed a new EGFR exon 20 insertion mutation in liver metastases which was confirmed to be squamous cell carcinoma. There are three possible mechanisms to explain the tumor evolution in this patient. First, tumor cells acquire a different phenotype under the pressure of the irreversible pan-EGFR family inhibitor afatinib. The transformation results from molecular changes associated with afatinib treatment. EGFR exon 20 and PIK3CA mutations reportedly may be associated with squamous cell carcinoma.3Li S. Li L. Zhu Y. et al.Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.Br J Cancer. 2014; 110: 2812-2820Crossref PubMed Scopus (164) Google Scholar Second, the original tumor may be a mixed-type lung cancer such as an adenosquamous carcinoma, with two different types of EGFR mutations. Third, a second primary cancer appears. In conclusion, this case suggests that the evolution of extracranial lesions is different from LM in tumor morphology and gene inheritance. The combination of osimertinib, bevacizumab and chemotherapy effectively controlled LM and extracranial lesions. This study was supported by the Zhejiang province Medical Science and Technology Project (2018KY313). The authors thank the patient and his family. Download .doc (.05 MB) Help with doc files Supplemental Table 1

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells

Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis

Randomized Phase 3 Study of First-Line AZD3759 (zorifertinib) Versus Gefitinib or Erlotinib in EGFR-mutant (egfrm+) Non–small-Cell Lung Cancer (NSCLC) with Central Nervous System (CNS) Metastasis.

Successful salvage therapy with cetuximab-based modalities in the non-sensitive EGFR-mutant lung cancer patients with leptomeningeal metastasis who have heavily pretreated histories.

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Treatment Response to Osimertinib in EGFR-Mutated Leptomeningeal Metastases from Non-Small Cell Lung Cancer: A Case Series.

Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report

Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports

Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor

Ott_a_199452 7785..7790

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor

Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report

AZD3759 Enhances Radiation Effects in Non-Small-cell Lung Cancer by a Synergistic Blockade of Epidermal Growth Factor Receptor and Janus Kinase-1

Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient with Afatinib-Resistant Lung Cancer

Successful Therapy Using High-Dose Furmonertinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastasis: a Case Report and Literature Review

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( EGFR m + ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.

Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report

High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study